• LAST PRICE
    8.3200
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.8200/ 2
  • Ask / Lots
    9.9700/ 10
  • Open / Previous Close
    0.0000 / 8.3200
  • Day Range
    ---
  • 52 Week Range
    Low 6.0500
    High 27.5650
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 7.76
TimeVolumeGLUE
09:32 ET4167.9
09:36 ET2007.77
09:45 ET609528
09:48 ET1008.07
09:54 ET11817.92
09:56 ET2007.89
09:57 ET2007.965
09:59 ET1007.9625
10:01 ET2007.93
10:03 ET2007.9675
10:06 ET1007.99
10:10 ET1007.995
10:12 ET3007.955
10:14 ET1007.955
10:15 ET38108.12
10:17 ET1008.12
10:19 ET6428.13
10:21 ET3008.13
10:28 ET19008.07
10:35 ET2008.165
10:37 ET10878.18
10:39 ET2048.18
10:48 ET1008.215
10:53 ET1008.215
10:55 ET8308.205
10:57 ET27988.235
11:00 ET1008.26
11:04 ET13978.3
11:08 ET1008.345
11:09 ET42008.26
11:15 ET1008.245
11:20 ET10368.29
11:24 ET1028.285
11:26 ET1008.285
11:29 ET2008.275
11:31 ET22008.255
11:33 ET4008.21
11:36 ET9008.205
11:38 ET2008.185
11:40 ET5008.1909
11:42 ET4008.185
11:44 ET37178.29
11:45 ET6018.3
11:47 ET4008.29
11:56 ET1008.265
11:58 ET2008.26
12:00 ET8858.26
12:02 ET4008.3
12:03 ET1008.3
12:05 ET1008.29
12:09 ET28958.305
12:16 ET2918.33
12:20 ET44318.37
12:27 ET2008.3
12:30 ET1008.29
12:32 ET11398.29
12:36 ET2008.28
12:38 ET21988.3
12:45 ET12068.31
12:48 ET8058.28
12:50 ET16028.3
12:52 ET1008.29
12:56 ET1008.29
12:57 ET125718.26
12:59 ET8008.215
01:01 ET1038.2215
01:06 ET3008.22
01:08 ET9008.26
01:10 ET1008.28
01:14 ET1008.25
01:17 ET1008.25
01:19 ET1008.225
01:21 ET6928.27
01:24 ET2008.28
01:26 ET2258.26
01:28 ET5008.245
01:30 ET1008.24
01:32 ET1008.235
01:33 ET2008.21
01:35 ET2008.205
01:37 ET1008.19
01:39 ET3008.15
01:42 ET1008.16
01:44 ET2008.14
01:46 ET1008.11
01:48 ET8008.16
01:55 ET10008.07
01:57 ET5008.085
02:00 ET7228.11
02:04 ET1008.11
02:11 ET1008.09
02:13 ET6008.13
02:15 ET3848.12
02:20 ET2008.15
02:24 ET1008.11
02:26 ET8008.08
02:27 ET9008.13
02:36 ET1008.105
02:38 ET7528.17
02:42 ET1008.15
02:45 ET3088.13
02:47 ET1008.09
02:49 ET1008.08
02:51 ET5668.12
02:56 ET1008.126
03:00 ET1008.09
03:02 ET5008.105
03:03 ET8558.12
03:05 ET1008.17
03:09 ET4008.15
03:12 ET1008.14
03:14 ET1008.14
03:16 ET3008.135
03:18 ET3008.12
03:20 ET3008.11
03:21 ET3008.11
03:23 ET25008.2
03:25 ET2008.2
03:30 ET2008.18
03:32 ET9998.23
03:34 ET10578.26
03:36 ET1008.24
03:39 ET2008.26
03:41 ET12388.26
03:43 ET3648.29
03:45 ET9008.29
03:48 ET1008.305
03:50 ET120938.345
03:52 ET21058.3
03:54 ET45568.355
03:56 ET50138.325
03:57 ET64778.32
03:59 ET117158.32
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGLUE
Monte Rosa Therapeutics Inc
344.7M
-4.1x
---
United StatesPRVB
Provention Bio Inc
334.4M
-2.8x
---
United StatesKALV
Kalvista Pharmaceuticals Inc
329.2M
-4.1x
---
United StatesBTAI
BioXcel Therapeutics Inc
315.3M
-2.7x
---
United StatesIVVD
Invivyd Inc
343.9M
-1.0x
---
United StatesAVTE
Aerovate Therapeutics Inc
378.2M
-11.4x
---
As of 2022-09-29

Company Information

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company. It is engaged in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops a protein degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN), that enables it to identify protein targets and molecular glue degrader (MGD), product candidates that are designed to eliminate therapeutically relevant proteins. It focuses on therapeutic targets backed by biological and genetic rationale discovering and developing novel precision medicines. Its lead product candidate is MRT-2359, which is an orally bioavailable degrader of the translation termination factor protein GSPT1 in development initially for use in the treatment of cancers. Its programs are focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways.

Contact Information

Headquarters
645 Summer Street, Suite 102BOSTON, MA, United States 02210
Phone
617-949-2643
Fax
302-655-5049

Executives

Non-Executive Chairman of the Board
Alexander Mayweg
President, Chief Executive Officer, Director
Markus Warmuth
Chief Financial Officer
Ajim Tamboli
Chief Technology Officer
Sharon Townson
Chief Scientific Officer
Owen Wallace

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$344.7M
Revenue (TTM)
$0.00
Shares Outstanding
46.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.02
Book Value
$7.47
P/E Ratio
-4.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.